Filing Flows › Emergent BioSolutions (EBS) › Stock forecast & fair value
Emergent BioSolutions (EBS) stock forecast and price target
Emergent BioSolutions (EBS) trades at $6.06. The analysts' price target is $10.00 (+65%).
Emergent BioSolutions' latest quarter
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for EBS stock?
The analysts' 12-month target is $10.00, +65% from $6.06. The average rating is buy.
Does Emergent BioSolutions usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is EBS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.